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Meningococci cc11 genomic characterization, Italy 137Results: Overall, 28 IMD cases due to meningococcus C were identified up to 31st October,
2015. Of them, 26 were due to meningococcus C:P1.5-1,10-8: F3-6:ST-11 (cc11) and 2 to
C:P1.5-1,10-8: F3-6:ST-2780 (cc11). WGS of 13 meningococci isolated during the outbreak
occurred in Tuscany in 2015 showed higher similarity when compared with those of 47 C:
P1.5-1,10-8: F3-6:ST-11 (cc11) invasive strains from sporadic cases previously detected in Italy.
Conclusions: A highly aggressive meningococcal C strain was involved in the cluster of severe
IMD occurred in Tuscany, a Region with high vaccine coverage among children. Whether this
was due to low herd immunity related to the short duration of vaccine protection needs further
investigation.
ª 2016 The Authors. Published by Elsevier Ltd on behalf of The British Infection Association.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
Italy is considered a country at low incidence of invasive
meningococcal disease (IMD), with predominance of the
meningococcal B and C capsular serogroups.1 However, IMD
cases due to serogroup C (MenC) declined after vaccine
introduction2 consistently with the trends observed in other
EU countries.3e7 In Italy, the use of the meningococcal C
conjugate (MCC) vaccine for children 13-to-15 month olds
and for adolescents 11-to-18 year-olds was recommended
by the Italian National Immunization Plan for the years
2012/2014.8 However, few Regions, like Tuscany, intro-
duced the MCC vaccine in the Regional immunization
schedule since 2005. Initially, the regional plan provided
three doses at 3, 5, and 13 months of age, switching to a
single dose at 13 months, with a catch-up immunization un-
til 6 years of age, in 2008.
In some Regions, a booster dose with the conjugate
vaccine against meningococcal A, C, W and Y was provided
to adolescents, people at risk, and travelers to endemic
areas.
A wide variation in vaccination coverage between Italian
Regions was observed, with values ranging between 42.72%
and 88.28%; in Tuscany the coverage was around 87.2% in the
birth-cohort of the year 2012 (http://www.salute.gov.it/
imgs/C_17_tavole_20_allegati_iitemAllegati_2_fileAllegati_
itemFile_0_file.pdf). Unfortunately, data on immunization
coverage for teens and at-risk groups were not available.
Despite the extended use of the vaccine, outbreaks and
smaller clusters of MenC belonging to the ST-11 clonal
complex (cc11) (MenC:cc11) have continued to occur in
Europe; in particular, the finetype C:P1.5-1,10-8:F3-6:ST-11
(cc11) was responsible of outbreaks in France and in
Germany.9,10
Since meningococci belonging to cc11 are considered
highly virulent and able to cause outbreaks, it is impor-
tant to identify and characterize this aggressive, vaccine
preventable strain. Hereby, we describe a cluster of
cases of IMD due to MenC:cc11 occurred between January
and October 2015 in Tuscany. In particular, we describe
the epidemic dynamics and the characteristics of the
strain involved in the outbreak up to that date. To this
end, the results of the whole genome sequencing (WGS),
and the geo/temporal distribution and characterization
of the isolates compared with other strains of the samefinetype identified in different geographical areas are
presented.
Materials and methods
IMD surveillance and control
In Italy, IMD cases are mandatorily reported, through the
Regions, to the Ministry of Health and to the Italian
Institute of Public Health (Istituto Superiore di Sanita,
ISS). The EU case-definition for lab-confirmed cases is
utilized.11 When a case of IMD is identified, contact tracing
and chemoprophylaxis are provided by the local health au-
thorities. In Tuscany, after the detection of an increase in
the number of IMD cases, a number of actions were under-
taken. Public health measures consisting in early detection
(i.e. 24 h rapid diagnosis using molecular methods) and
treatment of cases, antibiotic prophylaxis of close con-
tacts, active offer of the tetravalent vaccine to all teen-
agers (up to 20 years of age), and free-of-charge
vaccination of the adults (up to 45 years) living in the areas
at greatest risk. We defined an “high risk area” a province
with an observed number of cases in 2015 (up to October
31st) at least two-fold higher than expected (the number
of cases reported in the same province in the last 5 years).
The microbiological characterization of invasive menin-
gococcal strains was performed by the National Reference
laboratory (NRL) of the ISS. Epidemiological, clinical, and
microbiological data for each IMD case were managed using
a dedicated database.
Microbiological analyses
Isolates were cultured following standard procedures. The
serogroup was confirmed by slide agglutination with com-
mercial antisera (Remel Europe, Ltd, UK) or by multiplex
PCR.12 Susceptibility to cefotaxime, ceftriaxone, ciprofloxa-
cin, penicillin G, and rifampicin was determined by the MIC
Test Strip Method (Liofilchem, Italy) on Mueller-Hinton agar
(Oxoid), supplemented with 5% of sheep blood. The break-
points are those recommended by the European Committee
on Antimicrobial Susceptibility Testing e EUCAST version
5.0, January 1, 2015 (http://www.eucast.org/).
Genomic DNA was extracted using the QiAmp mini kit
(Qiagen, Hilden, Germany), according to the
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grown on Thayer Martin agar plate or directly from the
clinical sample, blood, or CSF (cerebrospinal fluid).
Multilocus sequence typing (MLST), PorA and FetA
typing, Bexsero antigen genes and antibiotic resistance
genes were defined as described in http://neisseria.org/.
The finetype is identified as follows: capsular group: porA
(P1). VR1,VR2: fetA VR: ST (cc).
Whole genome sequencing
The whole genome sequencing was performed on 60 Neisse-
ria meningitidis isolates at the Army Medical and Veterinary
Research Center in Rome.
For each isolate, 1 ng of DNA was used to prepare the
sequencing libraries, following the Nextera XT DNA pro-
tocol, according to the manufacturer’s instructions. WGS
of the isolates was performed by using the Illumina MiSeq
platform (kit v3, 600 cycles). On average, 1.9 million
paired-end reads were obtained for each sample. A first
quality check of the raw sequence data was performed
using FastQC.13 Reads were trimmed to keep high quality
bases (Q score >25) using the software Sickle,14 and de
novo assembly was carried out with the ABySS software
version 1.5.2 (k parameter Z 63).15 Contigs longer than
500 bp were selected using an ad hoc script and kept
for further analysis. The final assembly ranged from
201 to 506 (median Z 247) contigs/sample covering the
w2.2 Mb of the N. meningitidis genome.
Genome comparison
Draft genomes were uploaded to the PubMLST.org database
(http://pubmlst.org/neisseria/), which runs on the BIGSdb
platform.
Genomes were analyzed and compared using the BIGSdb
Genome Comparator tool implemented within the PubMLST
website (http://pubmlst.org/neisseria/), through the
gene-by-gene analysis approach. Phylogenetic analysis of
the 60 isolates was performed firstly exploring the 53 ribo-
somal protein (rMLST) genes. Then, the genomes were
investigated at higher resolution, analyzing the 1605 loci,
defined as the core genome in the PubMLST Neisseria data-
base (http://pubmlst.org/neisseria/), by the core genome
MLST (cgMLST) approach.
Incomplete loci were automatically removed from the
distance matrix calculation for the Neighbor-Net graphs.
The resulting distance matrices were visualized as
Neighbour-net networks, generated by SplitsTree4 (version
4.13.1).16
SNPs analysis
The program kSNP17 was used to identify core genome SNPs
on WGS data for each isolate. kSNP is based on k-mer anal-
ysis, therefore no multiple sequence alignment is required.
Before running kSNP, the program Kchooser was used to es-
timate the optimum value of k-mer that for N. meningitidis
data set was 31. After the kSNP analysis, the core_SNP_ma-
trix output file, containing only SNP loci common to all iso-
lates, was used for further analysis. Maximum Likelihoodanalysis18 on the core SNP matrix output of kSNP was per-
formed in MEGA 6.06,19 using the Bootstrap Method with
100 Bootstrap replications.Results
Epidemiological findings
From January 1st to October 31st 2015, 34 IMD cases were
detected in Tuscany; of them, 28 were due to MenC. IMD
cases were reported almost every week (Fig. 1) from
towns and villages between Florence and Pisa. No second-
ary cases were identified. As already mentioned, tradi-
tional measures, including chemoprophylaxis of close
contacts and vaccination of adolescents and adults, were
promoted by Local Health Authorities to contain the
spread of the disease. In particular, a catch-up strategy
was used for unvaccinated adolescents, whereas booster
doses were administered to those who had been previously
vaccinated.
In the first 10 months of 2015, the incidence of IMD due
to MenC in Tuscany was around 0.7 per 100,000 inhabitants,
which is almost 10-fold higher than expected for the entire
year in Tuscany since the introduction of MCC vaccination in
2005 (data not shown).
The median age of the patients was 25.5 years (average:
31 years), ranging from 9 to 82 years; 15 patients were
females and 13 males. Meningitis and septicaemia repre-
sented the main clinical picture (14 cases), followed by
septicaemia alone (13 cases), whereas only one patient
presented meningitis without sepsis. The outcome was fatal
for 6 patients who developed septicaemia or meningitis/
septicaemia.
Two patients had received the MCC vaccine 8 years
before the onset of the disease, and one patient 2 years
before; all the other patients were unvaccinated. The NRL
received samples from 26 of 28 IMD cases: 12 strains, 2
bacterial suspensions, and 12 clinical samples (CSF or
blood). All the 12 strains were susceptible to cefotaxime,
ceftriaxone, ciprofloxacin, and rifampicin, but showed a
decreased susceptibility to penicillin G (range
0.094e0.25 mg/L).Molecular analyses
Molecular analysis was performed on all 26 available
samples. MLST identified the ST-11 complex (cc11) as the
unique clonal complex. However, among cc11 isolates, two
different sequence types (STs) were found: ST-11 (24
samples) and ST-2780 (2 samples, ID 2670 and 2691). The
ST-2780 was identified in 2 strains isolated in April and May,
and differed from the ST-11 for 15 nucleotide in the fumC
gene.
Two different finetypes were identified: C: P1.5-1,10-8:
F3-6: ST-11 (cc11) in 24 samples (92.3%), and C: P1.5-1,10-
8: F3-6: ST-2780 (cc11) in 2 samples (7.7%).
The fHbp-1.13 variant was found in all but one analyzed
strains (ID 2639) that presented a fHbp allele 669, encoding
a truncated fHbp protein due to a frameshift mutation.
Figure 1 Timeline of serogroup C IMD cases occurred in Tuscany from January to October 31st 2015.
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with the Insertion Sequence (IS) disrupting the gene, as
already described for the ET-15 meningococci.20
As already described,21 a premature stop codon in the
aniA gene was also identified in all the samples.
Genome comparison
Whole genome analysis
Whole genome analysis was performed on 58 C: P1.5-1,10-
8: F3-6: ST-11 (cc11) strains and two C: P1.5-1,10-8: F3-6:
ST-2780 (cc11) collected in Italy from 2007 to 2015; out of
these strains, 6 were from an outbreak occurred in Veneto
in 2007, 4 from an outbreak occurred on a cruise ship in
Tuscany in 2012, and 13 from the current outbreak
(Tuscany, 2015); the remaining 37 were from sporadic IMD
cases.
rMLST
The analysis of 60 N. meningitidis isolates identified 9 ribo-
somal sequence type (rST). All isolates belonging to the
outbreak occurred in Tuscany in 2015 and 14 isolates
collected from sporadic cases in Italy between 2013 and
2015 grouped together in the same rST (data not shown).
cgMLST
Overall, 1349 of the 1605 core genome loci were included in
the cgMLST analysis, while the remaining 256 loci were
incompletely assembled. A total of 653 genes resulted
identical in all the 60 isolates.
The 60 meningococci were resolved by cgMLST analysis
(Fig. 2, panel a), revealing four groups: i) group I,
comprising 12 out of 13 meningococci identified in Tuscany
in 2015 and 14 meningococci isolated from sporadic cases in
Italy in 2013, 2014, and 2015, respectively (Fig. 2, panel b);
ii) group II, including 4 strains responsible of an outbreak
occurred on a cruise ship in 2012 in Tuscany22; iii) group
III, comprising the outbreak occurred in Veneto in 200723;
iv) group IV, including 1 strain isolated in Tuscany in 2015
(ID 2639) and 20 isolated from sporadic cases occurred in
Italy from 2012 to 2015. Three isolates from sporadic IMD
cases resulted distinct from the four groups.
Group I strains shared 1247 genes; in particular, those
strains isolated in Tuscany in 2015 showed 1287 identical
genes among them. The groups I and II, closer to eachother, shared 1157 exclusive identical genes. Groups III and
IV were in distal regions and shared respectively 1044 and
765 genes with group I.
cgMLST analysis pointed out 11 genes specific for each
group. For 5 of 11 genes, the function is known: NEIS0430,
hypothetically coding for a cytoplasmic axial filament
protein (cafA); the ctrE gene, involved in the capsule trans-
location, critical for transport of the mature lipidated poly-
mers to the meningococcal cell surface24; the rpsD gene,
coding for the 30S ribosomial protein S4; the tpsB gene, a
hemolysin activator; the penA, coding for the penicillin-
binding protein 2 (PBP2). The tpsB allele “new#1” harbors
a deletion of 1 adenine in the polyA stretch, causing a pre-
mature stop codon 150 bp downstream.
Table 1 listed the allelic profiles of the 11 genes for the
groups I and II, together with 3 representative genomes
available in the website (www.neisseria.org, last access
22nd September 2015) and identified in UK. The genomes
indicated in the Table 1 include those of meningococci
belonging to C:P1.5-1,10-8:F3-6:ST-11 (cc11) with the
penA 248 allele.
Concerning the 11 genes profile specific for each groups,
the main findings were:
i) 10 out of the 11 genes were identical in the group I;
NEIS0430 distinguished one subgroup within group I,
including all the genomes obtained from strains isolated
in Tuscany in 2015, and 4 from sporadic cases occurred in
Italy; ii) genomes of the group II, obtained from the
outbreak strains occurred in Tuscany in 2012, were iden-
tical to each other; in particular, the genomes obtained
from these strains showed 3 genes (NEIS0430, ctrE, and
rpsD) identical to the genome identified in UK ID21253;
moreover, they showed also the NEIS1858 gene identical
to the UK genome ID 30209; iv) the genomes obtained
from strains isolated in Tuscany in 2015 were identical to
the UK ID 21253 genome.
SNPs analysis
A Neighbor Joining analysis was performed on 60 N. menin-
gitidis strains using 2885 core SNPs obtained by the kSNP
analysis of WGS data (Fig. 3). All the strains involved in
the cluster occurred in Tuscany in 2015, with the exception
of the strain 2639, grouped together. The strain 2639
showed a unique SNP profile, similar to those of strains
Figure 2 Panel (a), Neighbour-net phylogenetic network based on a comparison of 1349 core genome loci (cgMLST) among 58 N.men-
ingitidis C: P1.5-1,10-8: F3-6: ST-11 (cc11) and 2 C: P1.5-1,10-8: F3-6: ST-2780 (cc11). Panel (b) Neighbour-net phylogenetic network
based on a comparison of 1360 core genome loci (cgMLST) among 26 isolates of the group I; ID of isolates responsible for serogroup C
IMD cases in Tuscany in 2015 are marked. The scale bars indicate the number of differences among the compared loci.
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Table 1 Allelic profiles of 11 genes characterizing groups I and II as defined by cgMLST analysis of meningococci isolated in Italy and of 3 representative meningococcal ge-
nomes available at http://pubmlst.org/Neisseria (last access 22nd of September 2015), selected by finetype C:P1.5-1,10-8:F3-6: ST-11 (cc11) and penA 248 allele.
ID
(ID http://pubmlst.org/Neisseria)
Country Year Group in the
cgMLST tree
NEIS0430 ctrE rpsD tpsB NEIS0263 NEIS0264 NEIS0265 NEIS0745 NEIS1594 NEIS1858 penA
2539 (37600) Italy 2013 I 6 355 29 new#1 144 10 28 176 271 157 248
2493 (37594) Italy 2013 I 6 355 29 new#1 144 10 28 176 271 157 248
2541 (38867) Italy 2013 I 6 355 29 new#1 144 10 28 176 271 157 248
2460 (38847) Italy 2013 I 46 355 29 new#1 144 10 28 176 271 157 248
2560 (36461) Italy 2014 I 46 355 29 new#1 144 10 28 176 271 157 248
2530 (37597) Italy 2014 I 6 355 29 new#1 144 10 28 176 271 157 248
2531 (37598) Italy 2014 I 6 355 29 new#1 144 10 28 176 271 157 248
2555 (37601) Italy 2014 I 6 355 29 new#1 144 10 28 176 271 157 248
2662 (36766) Italy 2014 I 6 355 29 new#1 144 10 28 176 271 157 248
2569 (36765) Italy 2014 I 398 355 29 new#1 144 10 28 176 271 157 248
2632 (36771) Italy 2015 I 6 355 29 new#1 144 10 28 176 271 157 248
2636* (36448) Italy 2015 I 398 355 29 new#1 144 10 28 176 271 157 248
2644* (36450) Italy 2015 I 398 355 29 new#1 144 10 28 176 271 157 248
2652* (36451) Italy 2015 I 398 355 29 new#1 144 10 28 176 271 157 248
2654* (36386) Italy 2015 I 398 355 29 new#1 144 10 28 176 271 157 248
2656* (36769) Italy 2015 I 398 355 29 new#1 144 10 28 176 271 157 248
2664* (36452) Italy 2015 I 398 355 29 new#1 144 10 28 176 271 157 248
2665* (36453) Italy 2015 I 398 355 29 new#1 144 10 28 176 271 157 248
2669* (36402) Italy 2015 I 398 355 29 new#1 144 10 28 176 271 157 248
2670* (36844) Italy 2015 I 398 355 29 new#1 144 10 28 176 271 157 248
2691* (36767) Italy 2015 I 398 355 29 new#1 144 10 28 176 271 157 248
2701* (36784) Italy 2015 I 398 355 29 new#1 144 10 28 176 271 157 248
2718* (38839) Italy 2015 I 398 355 29 new#1 144 10 28 176 271 157 248
2646 (36770) Italy 2015 I 398 355 29 new#1 144 10 28 176 271 157 248
2690 (36768) Italy 2015 I 398 355 29 new#1 144 10 28 176 271 157 248
2717 (38838) Italy 2015 I 398 355 29 new#1 144 10 28 176 271 157 248
2417** (36444) Italy 2012 II 6 209 1 1 1 1 1 1 1 3 248
2418** (36445) Italy 2012 II 6 209 1 1 1 1 1 1 1 3 248
2419** (36446) Italy 2012 II 6 209 1 1 1 1 1 1 1 3 248
2420** (36447) Italy 2012 II 6 209 1 1 1 1 1 1 1 3 248
M11 241039 (21253) UK 2011 na 6 209 1 new#1 144 10 28 176 271 157 248
M13 240628 (30209) UK 2013 na 6 209 1 new#1 144 10 28 176 271 3 248
M13 240155 (28093) UK 2013 na 6 355 29 new#1 144 10 28 176 271 157 248
*Tuscany 2015; ** Tuscany 2012; na: not applicable.
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Figure 3 Maximum Likelihood-based tree of 58 N. meningitidis C: P1.5-1,10-8: F3-6: ST-11 (cc11) and 2 C: P1.5-1,10-8: F3-6: ST-
2780 (cc11) constructed on 2885 core SNPs. ID of isolates responsible for serogroup C IMD cases in Tuscany in 2015 are marked with
an asterisk.
142 P. Stefanelli et al.from sporadic cases from other Italian Regions. The Be-
tween Groups Mean Distance was 0.038 between the Tus-
cany outbreak strains (Number core SNPs: 177) and the
isolates 2691 and 2670, which showed a different Sequence
Type (ST 2780).
The relatedness between the MenC strains isolated in
Tuscany in 2015 and in the 2012 outbreak was supported by
the number of base substitutions per site (Between Groups
Mean Distance in MEGA6) of only 0.071.
Discussion
In a 10 months period, 28 IMD cases due to serogroup C
within the cc11/ET-15 clonal complex were reported in a
geographically restricted area of Tuscany. All but two
isolates belonged to the finetype C:P1.5-1,10-8:F3-6:ST-11
(cc11). This strain had been already identified and charac-
terized in several European countries,9,10 including two
smaller outbreaks occurred in Italy.22,23
The number of IMD cases due to MenC reported in the
first 10 months of 2015 in Tuscany was higher than
expected. For comparison, in 2014, a total of 156 lab-
confirmed IMD cases was reported in Italy, and only two
were due to MenC; the majority of cases was due tomeningococcus B, as a consequence of the decline of
serogroup C cases among children 0e5 years old, following
the introduction of childhood vaccination. In Tuscany, the
incidence of IMD cases due to MenC was 0.2 cases/100.000
inhabitants before the introduction of MCC (2000e2005),
declining to 0.07 after the introduction of vaccination
(2006e2014), then showing this unexpected peak of 0.7 in
2015. This was to some extent surprising, since the
coverage of MCC vaccination in the Region was high.
Traditional measures, including chemoprophylaxis of
close contacts and vaccination of adolescents and young
adults, were implemented to contain the spread of IMD
cases. In particular, a catch-up strategy, boosting adoles-
cents who had been vaccinated and immunizing those who
had not been vaccinated before, was first implemented. In
fact, the lack of a catch-up program targeting adolescents
and young adults, who are considered the principal respon-
sible for carriage and transmission, is likely to explain at
least in part the excess of IMD cases observed in Tuscany.
Since several cases were reported among young adults, it
was then decided to offer the vaccine to all unvaccinated
individuals, up to 45 years old, living in the affected area.
Up to October 31st 2015, about 180,000 individuals have
been vaccinated (data not shown).
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by age category during the outbreak were not available.
Thus, the vaccination strategy was based on the assumption
of a rather short duration of protection among already
vaccinated infants and young children, and a rapid circu-
lation of MenC strains among unvaccinated adolescents and
young adults.25,26 To this regard, the MCC vaccine is likely
to provide high levels of direct protection in the short
term26,27 and to reduce the prevalence of serogroup car-
riage, improving the herd immunity in the overall popula-
tion.28,29 However, in areas where children are the main
vaccination target, a relatively short duration of protec-
tion, combined with low vaccine coverage in the adoles-
cence, may explain the occurrence of IMD cases among
unvaccinated individuals in older age-groups. In this
context, adolescents and young adults are known to have
the highest N. meningitidis carriage rates.30
As mentioned above, the outbreak was caused by the
hypervirulent clone C:P1.5-1,10-8:F3-6:ST-11 (cc11). To
support the analysis of the epidemic dynamics, whole
genome sequencing was performed to characterize the
Neisseria pathogenome, and to compare the genomic char-
acteristics of the 2015 Tuscany outbreak strains with those
of meningococci of the same finetype isolated in Italy over
the last years. Our findings indicate that all the C:P1.5-
1,10-8:F3-6:ST-11 (cc11) strains with penA248 isolated in
Italy show high similarity. This strain was identified for
the first time during the outbreak occurred on a cruise
ship docking in the port of Livorno, Tuscany, in 2012.22
Whether this event led to the introduction and spread of
this strain is matter of debate.
WGS may greatly contribute to outbreak investigation,
allowing the identification of specific lineages causing
disease in specific age-groups.31 Using conventional
methods able to characterize the finetype of each isolate,
strains collected from IMD cases occurred in Tuscany in
2015 appear similar to the other strains with the same fine-
type, which were responsible of sporadic cases occurring
throughout the country over the years. WGS and, in partic-
ular, core genome sequencing demonstrated that meningo-
cocci isolated in 2015 in Tuscany were closely related to
each other, whereas they differed from the strains sharing
the same finetype which had been isolated in other Italian
Regions. The SNP analysis confirmed the findings of cgMLST,
identifying the two strains with the same finetype but a
different ST (ST-2780).
As already mentioned by Lucidarme et al.,32 there are
several globally spread cc11 strains belonging to different lin-
eages. Our analysis suggests the relationship between the
2015 Tuscany outbreak strains and the cc11/ET15 sublineage
11.2 described by Lucidarme et al.32 Interestingly, several
C:P1.5-1,10-8:F3-6:ST-11 (cc11) isolated in the UK from
2011 to 201532 showed allelic profiles similar to those identi-
fied in the two outbreaks occurred in Tuscany in 2012 and
2015. The same sublineage 11.2 was also responsible of out-
breaks amongMSM in France andUK. It seems that themenin-
gococci of cc11/ET15 are rather homogeneous, but different
strains may emerge in different regions of the world.
Before drawing conclusions, possible limits of the study
should be mentioned. First of all, data on the carriage of
MenC strains involved in the outbreak are not available. To
this regard, although several studies showed low rates ofMenC carriage during outbreaks of MenC disease, a study
from Brazil found relatively high rates.33 The same study
suggested that the polysaccharide vaccine had no effect
on carriage, whereas the MCC was able to reduce it. Sec-
ondly, information on risk factors was not routinely and sys-
tematically collected. Thus, circulation dynamics and
infection modalities in the affected population remain
largely undefined. However, the characteristics of the cases
suggest a widespread circulation of MenC:cc11 among un-
vaccinated age cohorts. For this reason, it was decided to
vaccinate adolescents and young adults, who are likely to
sustain MenC circulation and represent the population
where IMD cases were mostly concentrated.
In conclusion, our findings show that increased incidence
rates of IMD due to hypervirulent meningococcal strains
may occur, unpredictably, also in areas with high vaccina-
tion coverage among infants and young children. WGS
supports the hypothesis that C:P1.5-1,10-8:F3-6:ST-11
(cc11) is an hypervirulent, outbreak-associated, and
evolving strain, which is now spreading globally. Detailed
molecular information is key to better understand epidemic
and hyper-endemic dynamics, and to re-modulate vaccina-
tion strategies.
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